Crown Bioscience and The Jackson Laboratory Collaboration Enables Global Access to FATZO Mouse Model
Continued Collaboration Facilitates Global Distribution of Obesity, Metabolic Disease, and NASH Model and Priority Supply to CrownBio’s World-Class Cardiovascular, Obesity, and Metabolic Disease Platform
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research today announced an exclusive agreement with The Jackson Laboratory (JAX)
to utilize its world-class distribution channels to make the FATZO mouse model available to researchers globally.
As CrownBio’s exclusive distributor of the FATZO model, JAX, the independent, nonprofit biomedical research organization will utilize its expertise in the breeding, production, and delivery of high-quality mouse models to increase worldwide access with immediate effect. As part of the agreement, JAX will provide a prioritized model supply to support CrownBio’s global service platform in obesity, diabetes and associated indications.
A unique and proprietary model to CrownBio, the FATZO model, is a translationally-relevant, inbred polygenic mouse model ideal for the study of obesity, metabolic syndrome and diabetes, and drug development. The model is sensitive to developing obesity and metabolic syndrome under the influence of a high-fat diet, which has been demonstrated to be a significant factor in the human development of these conditions. The model also exhibits human-like disease progression, making it an ideal candidate for modeling human metabolic syndrome.
“I am excited that our ongoing relationship with The Jackson Laboratory has resulted in this agreement and will enable easier access to FATZO, thereby accelerating discovery in obesity, diabetes, and NAFLD/NASH,” said Dr. Jim Wang, senior vice president of CrownBio’s Cardiovascular and Metabolic Disease division.
To learn more about the FATZO mouse and Crown’s Cardiovascular and Metabolic Disease platform, visit: www.crownbio.com/cvmd
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc.
The Jackson Laboratory
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Jobindex A/S18.3.2019 22:08:24 CET | Pressemeddelelse
Jobindex Årsrapport for 2018
Abeona Therapeutics Inc.18.3.2019 21:46:12 CET | Pressemeddelelse
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Open Compute Project Foundation15.3.2019 15:56:37 CET | Pressemeddelelse
Switch Datacenters’ Amsterdam 1 Datacenter Achieves OCP-Ready™ Status
IDEAL INDUSTRIES, INC.15.3.2019 15:09:31 CET | Pressemeddelelse
IDEAL INDUSTRIES, INC. Acquires Cree Commercial Lighting and Intelligent Lighting Control Systems
Bombardier Inc.14.3.2019 13:45:49 CET | Pressemeddelelse
Bombardier Announces Expiration of Early Tender Date and Amendments for its Cash Tender Offers for up to US$975,000,000 Aggregate Purchase Price of its 6⅛% Senior Notes due 2021 and its 8.750% Senior Notes due 2021
Teledyne DALSA14.3.2019 13:01:36 CET | Pressemeddelelse
New 3D laser profiler series excels at in-line measurement and inspection tasks
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum